Trending menu:
News
-
27 January 2020
AstraZeneca reports positive data for Brilinta in stroke patients
AstraZeneca has reported that the Phase III THALES clinical trial of Brilinta (ticagrelor) has met its primary endpoint in patients who had a minor acute ischaemic stroke or high-risk transient...
-
27 January 2020
Roche’s Tecentriq fails in Phase III urothelial cancer study
Results from the Phase III IMvigor010 clinical trial have revealed that Roche's Tecentriq (atezolizumab) did not meet the primary endpoint as an adjuvant monotherapy in muscle-invasive urothelial cancer (MIUC) patients.
-
27 January 2020
Ipsen temporarily stops palovarotene dosing in FOP trials
Ipsen has paused the dosing of patients in Phase II extension and Phase III clinical studies of palovarotene for the treatment of fibrodysplasia ossificans progressiva (FOP).
-
24 January 2020
BlackThorn begins Phase II dosing of BTRX-140 for depression
BlackThorn Therapeutics has commenced dosing of BTRX-335140 (BTRX-140) in a proof-of-concept Phase II clinical trial involving patients with major depressive disorder.
-
23 January 2020
OncoSec purchases Phesi ClinSite licence for immune-oncology trials
OncoSec Medical has secured a multi-year ClinSite licence from clinical development analytics products and services provider Phesi.
-
23 January 2020
LB Pharmaceuticals starts dosing of schizophrenia drug
US-based biotechnology company LB Pharmaceuticals has started the dosing of LB-102, a benzamide formulation intended for the treatment of patients suffering from schizophrenia, in a Phase I trial.
-
23 January 2020
Ionis and Akcea announce positive data for hypertriglyceridemia
Ionis Pharmaceuticals and its affiliate Akcea Therapeutics have reported positive data from the Phase II clinical trial of AKCEA-APOCIII-L conducted in hypertriglyceridemia patients with or at risk of cardiovascular disease...
-
23 January 2020
Roche says risdiplam met primary endpoint in type 1 SMA patients
Top-line data from part two of the open-label FIREFISH study has demonstrated that Roche’s risdiplam met the primary endpoint in babies with type 1 spinal muscular atrophy (SMA).
-
22 January 2020
Summit invests in data software specialist eClinical Solutions
Global Cloud-based enterprise software and software-driven clinical data solutions provider eClinical Solutions has received a minority investment from global growth equity firm Summit Partners.
-
22 January 2020
Rafael Pharmaceuticals studies combination therapy for biliary cancer
Rafael Pharmaceuticals has partnered with Michigan Medicine to start a Phase Ib/II clinical trial of devimistat (CPI-613) combination for locally advanced, unresectable or metastatic biliary tract cancer.